H. Lundbeck, Azilect® (rasagiline) approved in the EU

H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd. (Teva) announced today that the European Commission has given the final EU marketing authorisation for Azilect® for the treatment of Parkinson's disease both as initial monotherapy in patients with early Parkinson’s disease (PD) and as adjunct treatment in moderate-to-advanced PD. The companies intend to market the product in various countries across Europe during the second quarter 2005.